1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CC2D0CD0D4BC3ABD85257416006BEECC
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-continuing-medical-education-programs-and-activities?opendocument
18
19opendocument
2035.172.195.49
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing Marketing Management Pharmaceutical Speaker Training and Development

Benchmarking Continuining Medical Education (CME) Programs and Activities

ID: 4995


Features:

17 Info Graphics

25 Data Graphics

250 Metrics

80 Narratives

14 Best Practices


Pages/Slides: 80


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • SPECIAL OFFER
With limited information on actual return on investment for expenditures toward support of Continuing Medical Education activities, Pharmaceutical and Biotechnology companies are anxious to understand the value of CME support and strategies for ensuring investments provide appropriate impact on healthcare practitioner behaviors and patient outcomes. With this understanding, this study was undertaken utilizing key benchmark metrics and executive insights to assess current trends and future directions of CME in North America and Europe to map a path to future success in support of CME.

Industries Profiled:
Pharmaceutical; Biotech; Health Care; Medical Device; Chemical


Companies Profiled:
Alcon; Novo Nordisk; Roche; HemoCue; AstraZeneca Pharmaceuticals; Vianex; Amylin; Boehringer Ingelheim; Baxter Healthcare; Bristol-Myers Squibb; Celgene; Janssen; Lilly; Merck; Ortho-Clinical Diagnostics; Pfizer; Sanofi-aventis; Talecris

Study Snapshot

This research was based on benchmark survey data and executive interviews of 30 participants from 26 pharmaceutical, biotechnology and medical education companies.

Key topics include:

  • What is the current landscape of continuing medical education (CME) in North America and Europe?
  • What structural forms are used to deploy CME, optimize budgets & best deliver content?
  • How rapidly is E-CME advancing?
  • What CME delivery channels are preferred?
  • What are the current trends and future directions of CME?

Sample Key Findings

Decentralized management structures are most common across the global CME landscape
  • The Internet delivers on average between 10-25 percent of global CME content. CME leaders estimate this will double in the next three to five years
  • Face-to-face delivery of CME content is the most common delivery form in Europe and North America but it is also one of the least effective

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.